Administration of insulin-like growth factor (IGF) binding protein, specifically IGFBP-3, reduced HIF-1α/HIF-2α signaling, which mediates VEGF expression, and IGF-I production, contributing to reduced VEGF expression, airway inflammation, and bronchial hyperreactivity [147]. The gene discussed is IGF1; the disease is asthma.